We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Severe de‐novo palmoplantar and nail psoriasis complicating Nivolumab treatment for metastatic melanoma.
- Authors
Di Altobrando, Ambra; Bruni, Francesca; Alessandrini, Aurora; Starace, Michela; Misciali, Cosimo; Piraccini, Bianca M.
- Abstract
Nivolumab, a fully human IgG4 immune checkpoint modulator, binds to the programmed cell death 1 (PD‐1) receptor on T cells and blocks their inhibition. Thus, it increases the anticancer host immune response by allowing T cells to attack tumor cells. Although anti‐PD‐1 immunotherapy is typically well accepted, deregulation of immune tolerance caused by nivolumab may determine immune‐related adverse events, among which skin toxicities represent the most common. We report a case of severe new‐onset palmoplantar and nail psoriasis after receiving nivolumab treatment for metastatic melanoma.
- Subjects
PSORIASIS; MELANOMA; IMMUNOLOGICAL tolerance; CELL receptors; NAIL diseases; T cells; PALMOPLANTAR keratoderma
- Publication
Dermatologic Therapy, 2020, Vol 33, Issue 3, p1
- ISSN
1396-0296
- Publication type
Article
- DOI
10.1111/dth.13363